PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib - Full Text View

Sponsors and Collaborators:	Helsinki University Bayer
Information provided by:	Helsinki University
ClinicalTrials.gov Identifier:	NCT00117299

Purpose

This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec). The study participants are required to have histologically confirmed GIST with prior imatinib treatment for metastatic GIST. is administered orally 1250 mg/day. Six patients will first enter the study. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol in two stages (a maximum of 45 patients will be entered). Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.

Condition	Intervention	Phase
Sarcoma	Drug: PTK787/ZK222584	Phase II

MedlinePlus related topics: Cancer Soft Tissue Sarcoma

Drug Information available for: Imatinib Vatalanib Imatinib mesylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GISTs) Resistant to Imatinib Mesylate

Further study details as provided by Helsinki University:

Primary Outcome Measures:

Response rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment:	45
Study Start Date:	September 2004
Study Completion Date:	January 2009
Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental PTK/ZK o.d. 1250 mg p.o.	Drug: PTK787/ZK222584 PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally

Detailed Description:

This is an open-label, phase II study of PTK787/ZK222584 designed to determine the safety and efficacy of PTK787/ZK222584 in the treatment of imatinib-resistant GIST. The PTK787/ZK222584 dose used is 1250 mg daily. Six patients will first enter the study using a two-stage approach. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol (a maximum total number of 45 patients will be entered). Clinical benefit is defined as the occurrence of one or more of the following 3 measures: 1) objective response to PTK787 (a confirmed or unconfirmed partial response [PR] or a complete response [CR]); 2) metabolic response defined as >50% decrease in the standardized uptake value (SUV) of FDG uptake in >1 FDG-avid lesions in one or more of the patients; or 3) stabilized disease for 3 months or longer accompanied by symptomatic or performance status improvement. Medical history, current medical conditions, weight, height, and an electrocardiogram are recorded prior to the study entry. Other baseline examinations include a chest X-ray, hematologic tests, a coagulation panel, serum chemistries, urine analysis, a serum pregnancy test and a radiological assessment of the tumor. Tumor response is monitored with imaging at 4- to 8-week intervals. Hematological tests and serum chemistries are evaluated at 1- to 4-week intervals, and adverse events are collected continuously. Research blood tests are collected at the times of tumor evaluations. Dose adjustments are carried out as per the protocol. Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with histologically confirmed GIST
Imatinib resistance (primary resistance with progression, or progression after initial response). Resistance is defined as objective evidence of progression after at least 4 weeks of treatment with imatinib.
Imatinib therapy has been interrupted >7 days before study entry
Metastatic disease confirmed histologically, cytologically or radiologically
Presence of measurable tumor lesions as determined by RECIST criteria
Age 18 years or older
WHO performance status of 2 or less
Blood neutrophil count (ANC) 1.5 x 10^9/L or higher
Platelet count 100 x 10^9/L or higher
Serum bilirubin 1.5 x ULN (upper limit of normal) or less
Serum creatinine 2.0 x ULN or less
Written informed consent obtained according to local guidelines

Exclusion Criteria:

Patients who have received chemotherapy less than 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
Patients who have received a cumulative dose of doxorubicin >450 mg/m2 or epirubicin 800 mg/m2
Patients who have received immunotherapy within 2 weeks or who have not recovered from side effects of such therapy
Patients who have received radiotherapy within 2 weeks or who have not recovered from side effects of such therapy
Major surgery within 2 weeks prior to entry into this study or patients who have not recovered from side effects of such therapy
Patients who have received investigational drugs within 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control
Concurrent severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months, poorly controlled hypertension, history of labile hypertension, history of poor compliance with antihypertensive regimen, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
Acute or chronic liver disease (e.g., hepatitis, cirrhosis)
Confirmed diagnosis of HIV infection
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK222584 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the capsules/tablets)
Patients who are taking Coumadin (warfarin sodium); heparin is acceptable.
Patients unwilling to, or unable to, comply with the protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00117299

Locations

Finland
Helsinki University Central Hospital
Helsinki, Finland, FIN-00029

Sponsors and Collaborators

Helsinki University

Bayer

Investigators

Principal Investigator:

Heikki Joensuu, M.D.

Department of Oncology, Helsinki University Central Hospital

More Information

No publications provided

Responsible Party:	Helsinki University central Hospital ( Heikki Joensuu )
Study ID Numbers:	CPTK787 A2401/300267, GIST PTK787/ZK222584
Study First Received:	June 30, 2005
Last Updated:	February 3, 2009
ClinicalTrials.gov Identifier:	NCT00117299 History of Changes
Health Authority:	Finland: National Agency for Medicines

Keywords provided by Helsinki University:

Gastrointestinal stromal tumor
GIST
Sarcoma
PTK787
ZK 222584
Tyrosine kinase inhibitor
Tyrosine kinase
VEGF

Vascular endothelial growth factor
VEGFR
Vascular endothelial growth factor receptor
KDR
KIT
c-KIT
Platelet derived growth factor receptor
PDGFR

Study placed in the following topic categories:

Digestive System Neoplasms
Gastrointestinal Diseases
Endothelial Growth Factors
Protein Kinase Inhibitors
Vatalanib
Imatinib
Neoplasms, Connective and Soft Tissue

Malignant Mesenchymal Tumor
Soft Tissue Sarcomas
Digestive System Diseases
Sarcoma
Gastrointestinal Neoplasms
Mitogens
Gastrointestinal Stromal Tumors

Additional relevant MeSH terms:

Digestive System Neoplasms
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Growth Substances
Physiological Effects of Drugs
Enzyme Inhibitors
Endothelial Growth Factors
Protein Kinase Inhibitors

Pharmacologic Actions
Vatalanib
Neoplasms, Connective and Soft Tissue
Neoplasms
Neoplasms by Site
Digestive System Diseases
Sarcoma
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors

ClinicalTrials.gov processed this record on May 07, 2009